Cargando empresa
Just reported
Q3 2026 results
From Omnicell's results release of 29 de octubre de 2026; its quarterly report has since been filed.
Revenue
Actual
307,9M US$
-0,9 % y/y
-1,4 % q/qGuided
304M US$
midpoint
Above guide+1,3 %EPS, GAAP
Actual
0,24 US$
+100 % y/y
-54 % q/qGuided
—
No guide given
Operating income, GAAP
Actual
14,9M US$
+81 % y/y
-54 % q/qGuided
—
No guide given
Company outlook
Q4 2026
- Revenue295M US$ – 301M US$-5,1 % y/y First given
- EPS, adjusted0,41 US$ – 0,49 US$First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Omnicell is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Health Information Services
Graded A or B and worth $2B or more: A first, then the largest.
VEEVVeeva Systems Inc.48,9B US$A+
BTSGBrightSpring Health Services, Inc.14,2B US$A
HNGEHinge Health, Inc.9,4B US$A+
HQYHealthequity, Inc.8,6B US$A+
DOCSDoximity, Inc.5,9B US$B+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct 2026CAGraded C, now A
Estados financieros completos →
Construido a partir de los propios informes de Omnicell, Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
